Search
Tideglusib
go.drugbank.com/drugs/DB12129ApprovedInvestigationalWithdrawnIt is reported to be a potent anti-inflammatory and neuroprotective that is a non-ATP competitive inhibitor of glycogen synthase kinase 3 (GSK-3). … [A31601] Tideglusib is being developed by the Spanish pharmaceutic company Zeltia group and its current status is withdrawn for the treatment of Alzheimer's disease as of 2012.
Categories: Heterocyclic Compounds, 1-Ring, Glycogen Synthase Kinase 3, antagonists & inhibitorsSynonyms: 4-BENZYL-2-(A-NAPHTYL)-1,2,4-THIADIAZOLIDINE-3,5-DIONE, 4-Benzyl-2-(naphthalen-1-yl)-1,2,4-thiadiazolidine-3,5-dioneHydrocodone
go.drugbank.com/drugs/DB00956ApprovedIllicitInvestigationalHydrocodone is a synthetic opioid derivative of codeine.[T116] It is commonly used in combination with [acetaminophen] to control moderate to severe pain. … Historically, hydrocodone has been used as a cough suppressant although this has largely been replaced by [dextromethorphan] in current cough and cold formulations.
Synonyms: 4,5-alpha-Epoxy-3-methoxy-17-methylmorphinan-6-oneMixtures: Vicodin ES, Vicodin ESZenocutuzumab
go.drugbank.com/drugs/DB15559ApprovedInvestigational[L51983] In May 2026, zenocutuzumab was granted additional approval by the US FDA for use in NRG1-positive cholangiocarcinoma. … [L51963] It works to attenuate aberrant cancer cell growth caused by genomic rearrangements involving the neuregulin 1 gene (NRG1), which is an oncogenic driver.
Synonyms: Immunoglobulin g1, bispecific, anti-(human epidermal growth factor receptors, her2 and her3) (humanized clone mcla-128 .gamma.1-chain), disulfide with humanized clone mcla-128 light chain, dimerNorgestimate
go.drugbank.com/drugs/DB00957ApprovedInvestigationalNorgestimate was first described in the literature in 1977. … [A191068] It is commonly formulated with [ethinylestradiol] as a combined oral contraceptive that can also be used to treat moderate acne vulgaris.
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesSynonyms: (17α)-17-(Acetyloxy)-13-ethyl-18,19-dinorpregn-4-en-20-yn-3-one 3-oxime, (+)-13-Ethyl-17-hydroxy-18,19-dinor-17α-pregn-4-en-20-yn-3-one oxime acetate (ester)Ubrogepant
go.drugbank.com/drugs/DB15328ApprovedInvestigational[A189195] The development of oral gepants, including ubrogepant, may therefore constitute a significant advance in migraine headache treatment and may become the new standard of therapy in the treatment … remain in clinical development.
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesVutrisiran
go.drugbank.com/drugs/DB16699ApprovedInvestigational[L34490,L42065] Vutrisiran is commercially available as a conjugate of N-acetylgalactosamine (GalNAc), a residue that enables the delivery of siRNA to hepatocytes. … [L42065] This siRNA therapeutic is indicated for the treatment of neuropathies associated with hereditary transthyretin-mediated amyloidosis (ATTR), a condition caused by mutations in the TTR gene.
Metrizoic acid
go.drugbank.com/drugs/DB09346ApprovedMetrizoic acid is a molecule used as a contrast medium. It present a higher risk of allergic reactions due to its high osmolality. Its approval has been discontinued by the FDA. … In general, the drug was well tolerated by patients during cardiac examinations [A32091].
Categories: Compounds used in a research, industrial, or household setting, X-Ray Contrast ActivityPefloxacin
go.drugbank.com/drugs/DB00487ApprovedA synthetic broad-spectrum fluoroquinolone antibacterial agent active against most gram-negative and gram-positive bacteria.
Categories: Topoisomerase II Inhibitors, 4-QuinolonesAtoltivimab
go.drugbank.com/drugs/DB15898ApprovedInvestigational(i.e. through Fc-mediated immune effector function) antibody effects to play a role in combatting EBOV infection. … [A221825, A221830] A recent large-scale study elucidated that both neutralizing and Fc-mediated functions of antibodies were important for therapeutic benefit in animal models of EBOV infection.
Tiratricol
go.drugbank.com/drugs/DB03604ApprovedInvestigational[L53383] It was first approved by the EMA on February 12, 2025 for the treatment of peripheral thyrotoxicosis in patients with monocarboxylate transporter 8 (MCT8) deficiency,[A274038] a disorder characterized … [A274073] Tiratricol is currently being investigated in US clinical trials.
Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 InducersSynonyms: (4-(4-HYDROXY-3-IODOPHENOXY)-3,5-DIIODOPHENYL)ACETIC ACID, BENZENEACETIC ACID, 4-(4-HYDROXY-3-IODOPHENOXY)-3,5-DIIODO-